Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Completed · Phase 1

Conditions studied: Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

In brief

PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

Key facts

Study ID

NCT01155817

Run by

Stanford University

People needed

33

Starts

2010-08-01

Expected to finish

2013-12-01

Last updated by the study team

2020-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States
• Colorado Blood Cancer Institute — Denver, Colorado, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
• Gordon and Leslie Diamond Health Care Centre Hematology Administration — Vancouver, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.